Bausch + Lomb is introducing its branded Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, following the Food and Drug Administration’s approval on Feb. 22.
The product is a gel drop formulation of loteprednol etabonate, which was designed with SubMicron technology for efficient penetration to key ocular tissues at a low preservative level and a pH close to human tears.
It is indicated for the treatment of postoperative inflammation and pain following ocular surgery.
“Lotemax SM is the culmination of our clinical experience with the loteprednol etabonate compound for more than two decades. We are extremely proud to make this new treatment option available, our most advanced loteprednol etabonate formulation to date, to help our customers address the needs of their patients undergoing ocular surgery who experience postoperative inflammation and pain,” U.S. president, Bausch + Lomb Joe Gordon said.